|
NCT06349512
|
68Ga-FAPI-46 PET/CT for Predicting Histological Response to Neoadjuvant Chemo-immunotherapy in Triple-negative Breast Cancer (FAP-IT)
|
En recrutement
|
19 octobre 2024
|
|
NCT03830788
|
Erectile Dysfunction in Good Prognosis Prostate Cancer: a Phase III Medico-economic Study Comparing Brachytherapy to Stereotactic Body Radiotherapy (TEMPOS)
|
En recrutement
|
02 octobre 2024
|
|
NCT05508867
|
A Phase 3 Randomized Clinical Study of MK-4280A (Coformulated Favezelimab [MK-4280] Plus Pembrolizumab [MK-3475]) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)
|
En recrutement
|
20 septembre 2024
|
|
NCT02355379
|
Randomised Phase III Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over Intergroup Trial: Ffcd, Gercor, Gerico, Unicancer-gi (ADAGE)
|
En recrutement
|
20 septembre 2024
|
|
NCT06599463
|
Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study (LARENA)
|
En recrutement
|
20 septembre 2024
|
|
NCT04823377
|
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer. (PACT-01)
|
En recrutement
|
20 septembre 2024
|
|
NCT04790682
|
LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer (LIBERTYLUNG)
|
En recrutement
|
20 septembre 2024
|
|
NCT05354765
|
Exploration of Adaptive Antitumoral Immune Cells Through Lymphapheresis in Cancer Patients : ALCYTA (ALCYTA)
|
En recrutement
|
20 septembre 2024
|
|
NCT05088395
|
Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4 (ALCINA4)
|
En recrutement
|
20 septembre 2024
|
|
NCT05475366
|
Pilot Study of Personalized First-line Chemotherapy Choice for Patients With Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures (PACsign) (PACsign)
|
En recrutement
|
20 septembre 2024
|
|
NCT04934865
|
Real Life Prospective Multicentric Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients : REAL-MOOV-LUNG (REAL-MOOV-LUNG)
|
En recrutement
|
20 septembre 2024
|
|
NCT05441163
|
ProActIF-01 Trial: Randomized Study of Evaluation of an Individualized Program of Nutrition and Adapted Physical Activity in Frail Patients With Advanced Lung or Digestive Cancers (ProActIF-01)
|
En recrutement
|
20 septembre 2024
|
|
NCT05634395
|
Digital Phenotyping (Physical Activity, Sleep) in Women Over 70 Years of Age Treated for Breast Cancer With Any Type of Treatment (GrannyFit)
|
En recrutement
|
20 septembre 2024
|
|
NCT05486182
|
Impact of 18F-fluoroestradiol (FES) Positron Emission Tomography (PET) on the Therapeutic Treatment of Metastatic Breast Cancer Ipatients, Initially ER Positive and HER2 Negative, in Relapse After First-line Therapy Combining Hormone Therapy (ESTROTIMP)
|
En recrutement
|
20 septembre 2024
|
|
NCT06195709
|
ECLECTIC: EstroTEP and Circulating Biomarkers to Determine the Optimal Second Line Therapy for ER-positive HER2-negative Metastatic Breast Cancer Patients (ECLECTIC)
|
En recrutement
|
20 septembre 2024
|
|
NCT06175390
|
Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer: A Phase II Trial (SKYLINE)
|
En recrutement
|
20 septembre 2024
|
|
NCT05665530
|
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With Relapsed/Refractory Hematologic Malignancies
|
En recrutement
|
20 septembre 2024
|
|
NCT03774732
|
PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer (NIRVANA-LUNG)
|
En recrutement
|
20 septembre 2024
|
|
NCT02884375
|
Elderly Cancer Patient: ELCAPA Cohort Survey (ELCAPA)
|
En recrutement
|
04 septembre 2024
|
|
NCT05697146
|
Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France: a National, Multicenter, Prospective, Non-interventional Study (RosaLEE)
|
En recrutement
|
04 septembre 2024
|
|
NCT05630105
|
National Cohort of Patients With Cowden's Disease and With a Constitutional Alteration of the PTEN Gene for the Prospective Assessment of the Risk of Cancer. (COCO)
|
En recrutement
|
04 septembre 2024
|
|
NCT05440331
|
Morbidity and Mortality in Operating Room: Surgery and Standardized Communication (HIATUS)
|
En recrutement
|
04 septembre 2024
|
|
NCT01689584
|
Study of Family COsegregation of Nucleotide VARiants in the Panel of Genes to Validate Their Use in Genetic Counseling (COVAR)
|
En recrutement
|
04 septembre 2024
|
|
NCT02416388
|
Phase II/III Randomized Study to Improve Overall Survival in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus Mycophenolate Mofetil Prophylaxis of Graft Versus Host Disease in Allografted Patients in First CR : a Backbone InterGroup-1 Trial (BIG-1)
|
En recrutement
|
04 septembre 2024
|
|
NCT03017573
|
Prospective Biobanking Study in Ovarian, Breast, Head and Neck and Cervical Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE) (SCANDARE)
|
En recrutement
|
04 septembre 2024
|
|
NCT03878342
|
Prospective Study of Omission of Whole-breast Radiotherapy Following Breast-conserving Surgery in Patients With Very Low Risk Ductal Carcinoma in Situ of the Breast (ROMANCE)
|
En recrutement
|
04 septembre 2024
|
|
NCT03576417
|
A Phase III Randomized Trial of Post-operative Adjuvant Nivolumab and Concomitant Chemo-radiotherapy in High-risk Patients With Resected Squamous Cell Carcinoma of Head and Neck (NIVOPOSTOP)
|
En recrutement
|
04 septembre 2024
|
|
NCT02912949
|
A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)
|
En recrutement
|
04 septembre 2024
|
|
NCT03876951
|
Prospective Multicenter Pilot Study to Evaluate the Accuracy of Percutaneous Biopsy by Vacuum-assisted Biopsy (VAB) to Assess Pathological Complete Response in Patients With Clinical and Radiological Complete Response After Neoadjuvant Chemotherapy (NeoVAB) (NeoVAB)
|
En recrutement
|
04 septembre 2024
|
|
NCT04290663
|
Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI Scintigraphy (INTERMEDIATE)
|
En recrutement
|
04 septembre 2024
|
|
NCT04720729
|
Chemotherapy Monitoring by Circulating Tumor DNA (ctDNA) in HER2 (Human Epidermal Growth Factor Receptor-2)- Metastatic Breast Cancer (MONDRIAN): a Phase 2 Study (MONDRIAN)
|
En recrutement
|
04 septembre 2024
|
|
NCT03498183
|
Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (Sup or Egal to 15 mm) Classified Bethesda III or IV on Cytology (MIBI-THYR)
|
En recrutement
|
04 septembre 2024
|
|
NCT03475953
|
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE)
|
En recrutement
|
04 septembre 2024
|
|
NCT04652076
|
A Randomized, Multicenter, Open Label, Phase I/II Study to Evaluate the Safety, Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination with Carboplatin Plus Paclitaxel And/or Pembrolizumab in Patients with Locally Advanced/metastatic Endometrial Carcinoma or Cervix Carcinoma Progressing/relapsing After At Least One Prior Systemic Chemotherapy. (GYNET)
|
En recrutement
|
04 septembre 2024
|
|
NCT04802590
|
A Randomized Phase II Trial Evaluating Ibrutinib Plus CD20 Ab and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
|
En recrutement
|
04 septembre 2024
|
|
NCT04025541
|
Analysis of Circulating Tumor Markers in Blood (ALCINA 2)
|
En recrutement
|
04 septembre 2024
|
|
NCT05439005
|
Opioid Free Versus Opioid Based Anaesthesia for Free Flap Reconstruction Surgery of the Breast: A Phase III Multicentric Randomized Controlled Study. (OFOBA)
|
En recrutement
|
04 septembre 2024
|
|
NCT05629585
|
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)
|
En recrutement
|
04 septembre 2024
|
|
NCT05514054
|
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence (EMBER-4)
|
En recrutement
|
04 septembre 2024
|
|
NCT04181203
|
An Open Label, Randomized, Phase III Study, Evaluating the Efficacy of a Combination of Apalutamide With Radiotherapy and LHRH Agonist in High-risk Postprostatectomy Biochemically Relapsed Prostate Cancer Patients (CARLHA-2)
|
En recrutement
|
04 septembre 2024
|
|
NCT05116475
|
Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases (ALADDIN)
|
En recrutement
|
04 septembre 2024
|
|
NCT05955170
|
Tucatinib in Combination With Oral Etoposide (VP16) - Trastuzumab in Patients With Metastatic HER2+ Breast Cancer After Progression Under Tucatinib-Capecitabine-Trastuzumab or Toxicity Related to Capecitabine: a Multicenter Phase II (TUC-TOC)
|
En recrutement
|
04 septembre 2024
|
|
NCT06084936
|
A Phase III, Open-Label, Multicenter Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator's Choice in Patients With Relapsed/Refractory Mantle Cell Lymphoma (GLOBRYTE)
|
En recrutement
|
04 septembre 2024
|
|
NCT05963997
|
A Phase 1b/2 Open-label Study of Samuraciclib in Combination With Elacestrant in Participants With Metastatic or Locally Advanced Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Breast Cancer (SUMIT-ELA)
|
En recrutement
|
04 septembre 2024
|
|
NCT03328078
|
An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
|
En recrutement
|
04 septembre 2024
|
|
NCT06275737
|
Trimodal Peri Operative Prehabilitation for Upper Oesogastric and Pancreatic Cancer: A Multicenter, Two-cohort, Open-label, Single-arm POP-UP GERCOR Study (POP-UP)
|
En recrutement
|
04 septembre 2024
|
|
NCT06284122
|
A Phase III Randomized, Open-label, International, Multicenter Study Evaluating the Efficacy and Safety of Mosunetuzumab Plus Lenalidomide in Comparison to Anti-CD20 Monoclonal Antibody Plus Chemotherapy in Subjects With Previously Untreated FLIPI 2-5 Follicular Lymphoma (MorningLyte)
|
En recrutement
|
04 septembre 2024
|
|
NCT05512364
|
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
|
En recrutement
|
04 septembre 2024
|
|
NCT03622333
|
Clinic, Pathologic and Genetic Characterization of Patients With Familial Carcinoid Tumors (Study From the GTE, Groupe d'étude Des Tumeurs Endocrines)
|
En recrutement
|
07 août 2024
|
|
NCT03275311
|
Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Data Platform: Evolution of the Therapeutic Care in Metastatic Breast Cancer Across the French Comprehensive Cancer Centers From 2008 (ESME-MBC)
|
En recrutement
|
20 mars 2023
|
|
NCT03848052
|
Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Data Platform: Evolution of the Therapeutic Care in Lung Cancer in France Since 2015
|
En recrutement
|
05 novembre 2022
|